Eli Lilly (LLY) has agreed to a $100 million deal with Australian biopharma CSL (CSLLY) for a license to explore new uses for the anti-IL-6 monoclonal antibody, clazakizumab. Currently in phase 3 trials for preventing cardiovascular events in those with end-stage kidney disease, Lilly aims to expand its applications. CSL will receive milestone payments and royalties on global sales for any new indications Lilly successfully develops. The antibody's mechanism involves blocking IL-6 from binding to its receptor, offering potential for treating various immuno-inflammatory conditions.
https://www.gurufocus.com/news/8625113/eli-lilly-lly-secures-license-for-clazakizumab-from-csl
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.